Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Retained Earnings (2020 - 2025)

Historic Retained Earnings for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to -$661.8 million.

  • Mirum Pharmaceuticals' Retained Earnings fell 667.54% to -$661.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$661.8 million, marking a year-over-year decrease of 667.54%. This contributed to the annual value of -$644.2 million for FY2024, which is 1581.01% down from last year.
  • Mirum Pharmaceuticals' Retained Earnings amounted to -$661.8 million in Q3 2025, which was down 667.54% from -$664.7 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Retained Earnings peaked at -$223.7 million during Q1 2021, and registered a low of -$664.7 million during Q2 2025.
  • In the last 5 years, Mirum Pharmaceuticals' Retained Earnings had a median value of -$497.0 million in 2023 and averaged -$466.4 million.
  • In the last 5 years, Mirum Pharmaceuticals' Retained Earnings crashed by 14525.88% in 2021 and then crashed by 667.54% in 2025.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' Retained Earnings stood at -$257.2 million in 2021, then plummeted by 52.76% to -$392.8 million in 2022, then tumbled by 41.6% to -$556.2 million in 2023, then decreased by 15.81% to -$644.2 million in 2024, then dropped by 2.74% to -$661.8 million in 2025.
  • Its last three reported values are -$661.8 million in Q3 2025, -$664.7 million for Q2 2025, and -$658.9 million during Q1 2025.